The Paediatric Society of New Zealand (PSNZ) has provided feedback on the recent proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD. The submission, prepared by the PSNZ Neurodevelopment Clinical Network, broadly supports the proposed changes while emphasising the need for specialist involvement and appropriate resourcing.
Key points from the submission include:
-
Retaining specialist oversight for diagnosis: PSNZ supports the requirement that ADHD diagnoses for individuals aged 17 and younger remain within specialist services. Given the complexities of ADHD and the need for accurate differential diagnoses, the expertise of neurodevelopmental specialists is essential.
-
Expanding prescribing authority: The Society endorses allowing nurse practitioners and general practitioners to continue prescribing stimulant treatments and managing Special Authority renewals—provided they receive adequate training, support, and resources.
-
Exploring the role of prescribing pharmacists: PSNZ encourages consideration of how pharmacists with prescribing authority could contribute to ADHD management, improving accessibility and continuity of care.
-
A multidisciplinary approach: Managing ADHD requires time, expertise, and a collaborative approach. Ideally, treatment should be delivered within a multidisciplinary framework to ensure tamariki and rangatahi receive the comprehensive care they need.
PSNZ believes that, with appropriate resourcing and safeguards, these changes will improve access to ADHD treatment while maintaining high-quality care.
The submission was co-signed by:
Dr Colette Muir, Co-Chair of the PSNZ Neurodevelopment Clinical Network and Developmental Paediatrician, and
Denise Janes, Co-Chair of the PSNZ Neurodevelopment Clinical Network and Clinical Lead Physiotherapist.
Read the full submission below 👇